Nitrofurantoin Tablets

This product is an antibacterial drug. Escherichia coli is mostly sensitive to this product, and some strains of Enterobacteriaceae such as Enterobacter aerogenes, Enterobacter cloacae, Proteus, and Klebsiella are sensitive to this product. Pseudomonas aeruginosa is usually resistant to this product. This product has antibacterial effects on Gram-positive bacteria such as Enterococcus. The antibacterial activity of this product is not affected by pus and tissue decomposition products. It is more active in acidic urine. The antibacterial mechanism is to interfere with the oxidoreductase system in the bacteria, thereby blocking its metabolic process.

The main ingredient of this product is nitrofurantoin, and its chemical name is 1-[[(5-nitro-2-furanyl)methylene]amino]-2,4-imidazoledione. The chemical structure is: Molecular formula: C8H6N4O5 Molecular weight: 238.16

This product is enteric-coated tablets, which appear yellow after removing the coating.

It is used for acute simple lower urinary tract infections caused by sensitive bacteria such as Escherichia coli, Enterococcus, Staphylococcus, Klebsiella, Enterobacter, etc., and can also be used for the prevention of urinary tract infections.

Oral administration. Adults take 50-100 mg once, 3-4 times a day. Low dose for simple lower urinary tract infection: Children over 1 month old take 5-7 mg/kg per day, divided into 4 doses. The course of treatment is at least 1 week, or at least 3 days after the urine culture turns negative. For patients who need to prevent recurrent urinary tract infection, adults take 50-100 mg per day before bedtime, and children take 1 mg/kg per day.

1. Gastrointestinal reactions such as nausea, vomiting, anorexia and diarrhea are more common. 2. Allergic reactions such as rash, drug fever, granulocytopenia, hepatitis, etc. may also occur. Hemolytic anemia may occur in patients with glucose-6-phosphate dehydrogenase deficiency. 3. Adverse reactions of the nervous system such as headache, dizziness, drowsiness, myalgia, nystagmus, etc. may occasionally occur. Most of them are reversible. In severe cases, peripheral neuritis may occur. Patients with existing renal impairment or long-term use of this product are more likely to develop this disease. 4. Nitrofurantoin may occasionally cause acute pneumonia symptoms such as fever, cough, chest pain, lung infiltration and eosinophilia, which may disappear quickly after drug discontinuation. Corticosteroids may alleviate symptoms in severe patients. Patients who take the drug for more than 6 months may occasionally develop interstitial pneumonia or pulmonary fibrosis. The drug should be stopped as soon as possible and corresponding measures should be taken.

It is contraindicated in newborns, pregnant women, patients with impaired renal function, and patients allergic to nitrofurantoin drugs.

Precautions for children: It is forbidden to use in newborns under 1 month old. Precautions for pregnancy and lactation: 1. Because nitrofurantoin can pass through the placental barrier and the fetal enzyme system is not fully developed, it is not suitable for pregnant women in the late pregnancy and is forbidden for pregnant women at full term to avoid the possibility of hemolytic anemia in the fetus. 2. A small amount of nitrofurantoin can enter breast milk and induce hemolytic anemia in infants, especially those with glucose-6-phosphate dehydrogenase deficiency. Breastfeeding should be stopped when taking this product. Precautions for the elderly: Elderly patients should use it with caution and the dosage should be adjusted according to renal function.

1. When drugs that can cause hemolysis are used in combination with nitrofurantoin, the hemolytic reaction may be increased. 2. When used in combination with hepatotoxic drugs, the hepatotoxic reaction may be increased; when used in combination with neurotoxic drugs, the neurotoxicity may be increased. 3. Both probenecid and sulfinpyrazone can inhibit the renal tubular secretion of nitrofurantoin, resulting in an increase in the latter's blood concentration and (or) a prolonged serum half-life, while the urine concentration is reduced and the efficacy is also weakened. The dosage of probenecid and the like should be adjusted.

Keep away from light and store in sealed container.

50 mg

36 months

Jilin Jiuyang Pharmaceutical Co., Ltd.

• Founded in:

  2003-05-30

• Address:

  Taonan City Tiedong 12th Committee 63rd Group

• Tax NO.:

  91220881764576122X

• Registered Funds:

  10 million yuan

• Email:

  Log in to view